Identification of osteopontin as a urinary biomarker for autosomal dominant polycystic kidney disease progression

Background Autosomal dominant polycystic kidney disease (ADPKD), one of the most common human monogenic diseases, is characterized by the presence of numerous fluid-filled renal cysts and is a leading cause of end-stage renal disease (ESRD). Urinary biomarkers may be useful for predicting the variab...

Full description

Saved in:
Bibliographic Details
Main Authors: Hyunsuk Kim (Author), Jinmo Sung (Author), Ju Young Bae (Author), Poongyeon Lee (Author), Yun Kyu Oh (Author), Hyunho Kim (Author)
Format: Book
Published: The Korean Society of Nephrology, 2022-11-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_9afda071d55e48cfa81d2c02c704f8b2
042 |a dc 
100 1 0 |a Hyunsuk Kim  |e author 
700 1 0 |a Jinmo Sung  |e author 
700 1 0 |a Ju Young Bae  |e author 
700 1 0 |a Poongyeon Lee  |e author 
700 1 0 |a Yun Kyu Oh  |e author 
700 1 0 |a Hyunho Kim  |e author 
245 0 0 |a Identification of osteopontin as a urinary biomarker for autosomal dominant polycystic kidney disease progression 
260 |b The Korean Society of Nephrology,   |c 2022-11-01T00:00:00Z. 
500 |a 2211-9132 
500 |a 2211-9140 
500 |a 10.23876/j.krcp.21.303 
520 |a Background Autosomal dominant polycystic kidney disease (ADPKD), one of the most common human monogenic diseases, is characterized by the presence of numerous fluid-filled renal cysts and is a leading cause of end-stage renal disease (ESRD). Urinary biomarkers may be useful for predicting the variable course of ADPKD progression from cyst growth to ESRD. Methods To identify candidate urinary biomarkers of ADPKD progression, we used CRISPR/Cas9 genome editing to generate porcine fibroblasts with mono- and biallelic ADPKD gene knockout (PKD2+/- and PKD2-/-, respectively). We then performed RNA-sequencing analysis on these cells. Results Levels of osteopontin (OPN), which is expressed by renal epithelial tubular cells and excreted into urine, were reduced in PKD2-/- cells but not in PKD2+/- cells. OPN levels were also reduced in the renal cyst cells of ADPKD patients. Next, we investigated whether OPN excretion was decreased in patients with ADPKD via enzyme-linked immunosorbent assay. OPN levels excreted into renal cyst cell culture media and urine from ADPKD patients were decreased. To investigate whether OPN can predict the rate of ADPKD progression, we compared urinary excretion of OPN in ADPKD patients with slow progression and those with rapid progression. Those with rapid progression had an estimated glomerular filtration rate of >60 mL/min/1.73 m2. Urinary OPN excretion levels were lower in rapid progressors than in slow progressors. Conclusion These findings suggest that OPN is a useful urinary biomarker for predicting ADPKD progression. 
546 |a EN 
546 |a KO 
690 |a autosomal dominant polycystic kidney disease 
690 |a biomarkers 
690 |a clustered regularly interspaced short palindromic repeats/cas9 
690 |a osteopontin 
690 |a Internal medicine 
690 |a RC31-1245 
690 |a Specialties of internal medicine 
690 |a RC581-951 
655 7 |a article  |2 local 
786 0 |n Kidney Research and Clinical Practice, Vol 41, Iss 6, Pp 730-740 (2022) 
787 0 |n http://www.krcp-ksn.org/upload/pdf/j-krcp-21-303.pdf 
787 0 |n https://doaj.org/toc/2211-9132 
787 0 |n https://doaj.org/toc/2211-9140 
856 4 1 |u https://doaj.org/article/9afda071d55e48cfa81d2c02c704f8b2  |z Connect to this object online.